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Abstract:
Melanoma is the most lethal form of skin cancer and accounts for the majority of
skin cancer deaths. Melanoma is prone to recurrence, and even with early surgical
intervention relapse occurs in approximately one-third of patients. The current standard
of care following excision is inconsistent and patients would benefit from adjuvant
treatment to reduce recurrence rates. This randomized controlled study will investigate
whether supplementation with vitamin D reduces risk of melanoma recurrence in adults
with Fitzpatrick skin types IV-VI who have been diagnosed and treated for cutaneous
melanoma. Outcomes will be measured by relapse-free survival rates over an 18-month
period. We hypothesize that the treatment group receiving vitamin D will have a lower
rate of relapse of melanoma compared to those not receiving vitamin D supplementation.
The results of this study will help inform melanoma management with the goals of
decreasing relapse rates in a higher risk patient population.
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Chapter I: Introduction
1.1 Background
1.1.1 Malignant Melanoma
Melanoma is a malignant tumor that arises from the proliferation of the pigmentproducing cells in the skin called melanocytes. Malignant melanoma is the most lethal
form of skin cancer and makes up the majority of skin cancer deaths.1 Cutaneous
melanoma is currently the 6th most common cancer in the United States with an
incidence of 21.3 per 100,000 per year. Although melanoma constitutes only 2.3% of all
skin cancer diagnoses it is responsible for 75% of all skin cancer deaths. 2 Melanoma is
one of the fastest growing cancers and its incidence has continued to rise over the last 50
years.1 From 1973 to 2002 the incidence of melanoma rose by 270% in the United
States, with the largest increases seen in white, elderly and female populations.3 Although
melanoma is more common in whites, people with skin of color have demonstrated more
advanced stages, thicker lesions, increased rates of metastasis, earlier age of diagnosis
and poorer outcomes. 4 Due to its high mortality rates, melanoma requires aggressive
treatment including early surgical excision.

1.1.2 Melanoma Standard of Care and Recurrence
Surgical excision is the current standard of care for the treatment of melanoma,
although the precise treatment approach depends on numerous prognostic factors
including the stage at diagnosis. Melanoma is excised with wide margins of 0.5-2 cm
depending on lesion characteristics. In addition, the current standard of care recommends
a sentinel lymph node biopsy to detect micrometastatic melanoma for patients with stages
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T2, T3, and T4. There are also a number of immunotherapies being used as adjuvant
treatments in unresectable or metastatic melanoma with some success.4 However, even
when patients undergo a complete excision of their primary melanoma, they are still at
risk for having a recurrence of the primary melanoma or developing a new melanoma.5
Recurrence rates in stage II-III melanoma have been found to be between 8 and 46%
depending on stage, and nearly one-third of all melanoma patients will experience some
form of disease recurrence.6-9 Approximately half of all recurrences are detected
clinically within the first two years, but the median time at which melanoma recurrence is
detected varies based on stage.6,9,10 This high rate of recurrence has led the medical
community to seek novel approaches to address the issue.
There are a number of adjuvant treatments being tested for malignant melanoma. A
2019 review of adjuvant therapy in melanoma discussed the use of radiotherapy, immune
therapy (such as interferon), immune checkpoint inhibitors, molecular-targeted therapy
and neoadjuvant therapies as adjuvant treatments in malignant melanoma. Some success
has been seen with these various treatments. However, none have become part of the
standard of care since the treatments have only been successful in specific situations
based on the characteristics of the melanoma and patient population. Many of the
beneficial medications for melanoma have been associated with toxic side effects, further
limiting their use.11 Ipilimumab was an early adjuvant treatment found to increase
relapse-free survival in malignant melanoma and accordingly was approved for adjuvant
use. It was later found to be associated with high toxicity, making its use controversial.
There are several new promising options being explored including PD-1 (programmed
cell death protein 1) inhibitors and molecular targeted therapies that still require further
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investigation prior to widespread use.12,13 There is also some evidence that nivolumab
may be a safer substitute for ipilimumab as an adjuvant treatment.14 Despite these recent
advances and interest in adjuvant treatments for malignant melanoma there is still a need
to explore novel options with lower toxicity and more general applicability to help
improve patient outcomes and to help establish more specific guidelines for standard of
care after surgical resection.

1.1.3 Vitamin D Properties and Absorption
Vitamin D is a steroid that can be obtained either through supplements, dietary intake
or ultraviolet radiation exposure and has minimal to no harm on the human body at
normal consumption levels. Vitamin D3 is transported to the liver through the
bloodstream. The circulating form of vitamin D, 25(OH)D3 is synthesized in the liver
through the hydroxylation of CYP2R1. It then travels to the kidney where it is converted
into the active form of vitamin D 1,25(OH)2D3 which is known as calcitriol. The active
calcitriol can then exert its various effects on the body.15,16 Sun exposure is important in
the synthesis of vitamin D (cholecalciferol) in the skin as it contributes to over 90% of
circulating serum Calcidiol (25(OH)D). Current cultural norms contribute to severely low
serum vitamin D levels in some groups. These norms are problematic since there is
emerging data suggesting that mild exposure to UV radiation (UVR) or dietary
supplementation with oral vitamin D can reduce cancer mortality.17 Deficiency in
25(OH)D3 is common in the US population but has been found to occur at a higher rate in
African American and Native American populations. 72.8% of healthy African
Americans and 19.6% of Native Americans are deficient in vitamin D, which is
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significantly higher than the 11.3% of European Americans who are vitamin D
deficient.15 These differences are related to the fact that white skin has been shown to
produce vitamin D more efficiently as it is able to synthesize vitamin D with lower levels
of sunlight and on cloudy days.18 Melanin acts as a UVR filter and accordingly, the
amount of melanin in the skin is inversely related to vitamin D production in the skin.
People with dark skin require at least 10 times more sun exposure than light-skinned
individuals to produce equal amounts of vitamin D in their skin.19 This evidence
demonstrates that vitamin D deficiency is far more common in those with darker skin,
and accordingly supplemental vitamin D may be beneficial for these populations.

1.1.4 Vitamin D and its Potential Role in Treatment
Previous biological and epidemiological data suggests that a patient’s vitamin D
status may affect their risk of cancer and play a role in cancer prevention through
antiproliferative effects. More research is required to confirm whether vitamin D has a
positive influence on the patient outcome. 20 The active form of vitamin D3 has been
shown to have anticarcinogenic and antimelanoma effects in experimental models
through interaction with the vitamin D receptor (VDR).21 Additionally, in vitro studies
have shown that vitamin D has multiple anti-cancer effects including promotion of cell
differentiation, apoptosis, inhibition of cell proliferation and tumor angiogenesis.5,22
Vitamin D may also have more pronounced local effects in the skin because of the
keratinocyte’s ability to synthesize calcitriol, the active form of vitamin D.17 Research
shows that calcitriol may also have anti-inflammatory effects which may contribute to its
anti-cancer properties.22
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Serum 25(OH)D is considered the best indicator of vitamin D status. It is the main
circulating form of vitamin D and is both relatively stable and has a long half-life of over
15 days. 23,24 The optimal level of vitamin D in an individual is a minimum of 30 ng/ml.
Less than 10 ng/ml is considered deficient, less than 20 ng/ml is considered vitamin D
insufficient and vitamin D becomes toxic at levels of 100-150 ng/ml. Vitamin D3
supplements are used to raise 25(OH)D concentrations.25 A 2010 study by Norman and
Bouillon showed that there is a good safety profile for the current recommended
additional vitamin D intake of 1,000 International Units (IU)/day.26 However, serum
concentrations of 25(OH)D reach a plateau after three months when given monthly
supplementation doses of 1,000 IU/d of vitamin D3.27 Supplementation with vitamin D3
can raise concentrations and still be safe when giving an oral loading dose of 500,000 IU
followed by an oral 50,000 monthly dose for 2 years.25 Vitamin D toxicity can occur at
very high doses, and the primary cause of the associated symptoms is hypercalcemia.
Calcitriol, the active form of vitamin D binds with high affinity to VDRs, which in turn
increases intestinal absorption of both calcium and phosphorus.24 According to a study
conducted by Vieth et al., vitamin D toxicity would require a minimum of 10,000 IU/day
and most likely would not occur at less than 40,000 IU/day.28
The effect of vitamin D on malignant melanoma is still not fully understood but may
be due to its non-calcemic systemic effects. Decreased levels of biologically active forms
of vitamin D3 can affect disease progression in melanoma and therefore it may be
beneficial to include vitamin D3 into melanoma management.29 Low levels of 25(OH)D
are associated with thicker tumors and reduced survival in melanoma patients.21,29 In
2015, an Australian study found a significant association between vitamin D levels and
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Breslow thickness, ulceration and mitotic rates. The average serum vitamin D levels were
higher in the tumors with better prognostic factors which included the tumors without
ulceration and with lower mitotic rates. Despite these findings, it is still unclear how
vitamin D supplementation influences melanoma incidence and outcomes. Regardless of
the mechanism, decreased levels of biologically active forms of vitamin D3 can affect
disease progression in melanoma. Accordingly, it may be beneficial to include vitamin D3
in melanoma managament.5,29 Adjuvant treatment with vitamin D in melanoma is
expected to reduce tumor invasiveness and local metastasis which would both improve
the patient’s prognosis and reduce their risk of relapse.30
Previous studies have found that vitamin D has the potential to be a valid coadjuvant
in the treatment of cancers such as melanoma but there is not currently research
confirming this hypothesis.31 It would be advantageous to conduct a randomized
controlled trial (RCT) investigating whether increasing vitamin D levels will help
improve melanoma outcomes. This would improve our understanding of the potential
role of vitamin D in melanoma treatment. Current studies are investigating the
relationship between vitamin D supplementation and cutaneous melanoma outcomes, but
their research has yet to be published.2,25 To further the research regarding the possible
protective effects of vitamin D supplementation on cutaneous malignant melanoma
following surgical resection of the primary melanoma, we will use a multicenter
randomized placebo-controlled trial with a follow-up period of 18 months. In addition to
investigating relapse-free survival, potential participants will be categorized by
Fitzpatrick skin types and would only be included if they are classified as having a
Fitzpatrick skin type IV, V or VI. This would allow us to determine whether vitamin D
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supplementation would be an effective adjuvant treatment for patients with darker
baseline skin tones. These categories of skin color were chosen based on prior studies
showing that individuals with darker skin have lower serum vitamin D levels due to
decreased synthesis in the skin.

1.2 Statement of the Problem
Melanoma rates continue to rise, and it continues to be the deadliest form of skin
cancer. Relapse after surgical excision is not uncommon and occurs in approximately
one-third of melanoma patients. The current standard of care following excision is
inconsistent and has prompted an interest in finding adjuvant treatments that could reduce
relapse rates. The active form of vitamin D3 has been shown to have anticarcinogenic,
anti-inflammatory and antimelanoma effects. Adjuvant treatment with vitamin D in
melanoma is expected to reduce tumor invasiveness and local metastasis, which would
both improve the patient’s prognosis and reduce their risk of relapse.30

1.3 Goals and Objectives
The primary goal of this study is to determine whether supplementation with
vitamin D3 increases relapse free survival and reduces risk of melanoma recurrence in
patients with darker skin tones. The proposed study will use a randomized controlled trial
design to establish a potential new adjuvant treatment post-surgical excision that could
decrease recurrence rates in patients with Fitzpatrick skin types IV, V, and VI.
Additionally, this study aims to determine whether the effectiveness of this treatment
varies by Fitzpatrick skin types.
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1.4 Hypothesis
There will be a statistically significant difference in relapse-free survival in
patients with Fitzpatrick skin types IV, V, VI provided with supplemental vitamin D3
after surgical excision compared to those without vitamin D3 supplementation.
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Chapter II: Review of the Literature
2.1 Introduction
An extensive literature search conducted between July 2019 and May 2020 aimed
to review studies that used vitamin D as an adjuvant treatment in melanoma treatment.
Databases including PubMed, Ovid MEDLINE, and Cochrane were searched using the
following keywords: melanoma, malignant melanoma, skin cancer, cancer, skin
neoplasms, vitamin D, and calcitriol. The search was limited to studies published since
2009 in order to focus on recent findings. All relevant articles written in English were
reviewed for significance to the current study.

2.2 Review of Relevant Studies
This section summarizes the existing evidence pertaining to the use of vitamin D
in cancer treatment and more specifically in melanoma treatment. There has been interest
in vitamin D as a preventative measure in cancer for a number of years due to its
anticarcinogenic properties but its use as an adjuvant treatment in melanoma is relatively
new and accordingly the data is limited. Therefore, the focus is on previous literature that
has investigated the relationship between vitamin D and tumor progression or formation.

2.2.1 Studies Analyzing the Relationship Between Vitamin D and Cancer
Many studies have investigated the efficacy of vitamin D supplementation in the
prevention of various cancers. A 2017 randomized controlled trial conducted across the
state of Nebraska by Lappe et al. assessed whether vitamin D3 and calcium
supplementation reduces the risk of cancer among postmenopausal women. They found
no statistically significant difference in incidence of any type of cancer after four years. A
11

post-hoc analysis excluding cancers diagnosed in the first year of the study, found a 35%
(Confidence interval (CI) 95%, p = 0.047) lower incidence of cancer in the active
intervention group. Some limitations of the study include that it was not sufficiently
powered to detect differences in cancer types between study groups and that its
population consisted of predominantly Caucasian women, limiting generalizability.
Another limitation was that the baseline average serum 25(OH)D level of the participants
was 32.8 ng/mL which is higher than the vast majority of the US population. This may
have affected the results as it would be expected that those with lower baseline serum
levels of vitamin D3 would benefit more from supplementation.1
The 2018 Vitamin D Assessment Study recruited adult participants in New
Zealand to assess whether high-dose vitamin D given monthly was associated with a
reduction in cancer incidence and mortality. The 5,108 participants were randomized to
receive either an initial 200,000 IU Vitamin D bolus followed by monthly doses of
100,000 IU or a placebo. The participants were followed for an average of 3.3 years. The
results of this study suggested that high dose vitamin D supplementation is not associated
with reductions in cancer incidence (95% CI, p=0.95) or mortality in the studied
population. Some limitations of this study included monthly dosing versus either weekly
or daily dosing. Using either daily or weekly dosing would increase the amount of time
vitamin D would be present in blood circulation. Additionally, the majority of the studied
population was Caucasian with European ancestry, and there was a low number of
participants that began the study with vitamin D deficiency.2
Another RCT was conducted by Manson et al. in 2019 to test whether vitamin D
and omga-3 fatty acid supplementation helped prevent cancer and cardiovascular disease.
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This randomized controlled trial used high dose daily vitamin D intervention and
included a large and ethnically diverse sample size of 25,871 participants. They did not
find a significantly lower incidence of invasive cancers (Hazard ratio (HR):0.96, 95%
CI, 0.88 to 1.06) or cardiovascular events (HR: 0.97, 95% CI, 0.85 to 1.12, p = 0.69) in
the treatment versus placebo group but did note that the test for proportionality over time
excluding early follow-up data did show a significantly lower death rate from cancer in
the treatment versus placebo group (HR: 0.75, 95% CI, 0.43 to 0.92). These findings may
indicate that vitamin D and omega-3 fatty acid supplementation is useful in cancer
prevention in tumors that have yet to begin formation or that are very early in growth.
Additionally, there were some non-significant but clinically meaningful differences seen
in the group receiving vitamin D including slightly fewer advanced cancers or cancers
that had metastasized. One limitation of this study was it was not powered to be able to
assess site specific cancers.3
Weinstein et al. performed a prospective study looking at 4,616 cancer cases from
a previous controlled primary prevention trial conducted from 1985-1988 in Finnish male
smokers. They examined the overall cancer mortality as well as site-specific mortality.
The researchers found that having a higher circulating 25(OH)D level years before their
cancer diagnosis was associated with lower overall cancer mortality (HR:0.76, 95% CI,
0.67 to 0.85, p-trend < 0.0001). They also found that having higher vitamin D levels
significantly improved survival in malignant melanoma (HR: 0.39, 95% CI, 0.20 to 0.78,
p-trend = 0.01), prostate cancer (HR:0.74, 95% CI, 0.55-1.01, p-trend = 0.005), and
kidney cancer (HR: 0.59, 95% CI, 0.35 to 0.98, p-trend = 0.28). There were nonsignificant improved survivals in other types of cancer as well. Their study did find an
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inverse relationship with high vitamin D levels and lung cancer survival. This study only
used vitamin D levels taken from a single point of time which may have limited the
accuracy of some of the measured associations. Additionally, all the participants were
male smokers which may have reduced the generalizability of the results.4
In 2019, Keum et al. performed a meta-analysis of RCTs investigating the effect
of vitamin D supplementation on total cancer incidence and mortality. They included 10
RCTs in their analysis of cancer incidence and 5 RCTs in their analysis of cancer
mortality. Overall, their meta-analysis revealed that vitamin D supplementation
significantly reduced cancer mortality by 13% (RR: 0.87, 95% CI, 0.78 to 0.96, p =
0.007) but did not reduce cancer incidence. It was also important to note that the
reduction in cancer mortality was seen more in trials using daily dosing versus infrequent
bolus dosing. The effects were seen in participants who had a circulating 25(OH)D level
of less than 100 nmol/l. The significant reduction in mortality but not in incidence was
thought to be in part due to vitamin D working at different stages of carcinogenesis
including decreasing the invasiveness and likelihood to metastasize. A strength of this
meta-analysis was that it was successful at analyzing the current trends being seen in the
associations between vitamin D supplementation and cancer incidence and mortality, but
it had some limitations. First, they only used 10 studies and there was no analysis of
cancer type-specific trends, meaning there may have been a greater effect for certain
types of cancer than others. Second, most of the study populations were predominantly
white and the results may not be very generalizable.5 This meta-analysis showed
evidence for vitamin D supplementation decreasing cancer mortality however there is
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still a lack of evidence on its effects in diverse populations and people with low baseline
levels of vitamin D.

2.2.2 Vitamin D Effects on Skin Cancer
Due to the trends seen in previous research in regard to vitamin D levels and
cancer, some studies examined the relationship between vitamin D supplementation and
skin cancer. Tang et al. performed a post-hoc analysis of the Women’s Health Initiative
Randomized Control Trial to examine whether supplementation with 400 IU of vitamin D
and 1,000 mg of calcium daily would change the incidence of skin cancer. They
examined 36,282 post-menopausal participants over a 7 year follow up. They found no
difference in non-melanoma or melanoma skin cancer incidences between groups, but
notably, they did find a 57% lower risk of melanoma in the treatment group compared to
controls among women who had a reported history of non-melanoma skin cancer (HR:
0.43, 95% CI, 0.21 to 0.90). It is important to note that they excluded women who had a
melanoma fewer than 10 years prior to the beginning of the study when examining these
results, as this potentially excluded melanoma recurrences. A limitation of this study is
that participants were allowed to take off-protocol calcium and vitamin D
supplementation making it possible that some women in the placebo group could have
been taking more vitamin D than in the intervention group due to the low dose of vitamin
D provided in the study.6
Caini et al. performed a meta-analysis assessing the effect of vitamin D on
melanoma and non-melanoma skin cancer risk and prognostic factors in 2014. They
included 20 studies with an overall number of 1,420 cutaneous melanoma cases and
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2,317 non-melanoma skin cancer (NMSC.) Their results were suggestive of an inverse
relationship between serum vitamin D levels and thickness of melanoma tumor at
diagnosis but they found no association with incidence and serum levels.7 Both this
meta-analysis and the Tang et al. study provide important evidence suggesting the role of
vitamin D in improving melanoma prognostic factors and risk.

2.2.3 Relationship Between Vitamin D and Melanoma
The potential relationship between vitamin D and melanoma was tested further in
a number of studies. A 2016 study conducted by Fang et al., assessed the association
between vitamin D levels and outcomes in patients with melanoma after adjustment for creactive protein (CRP). They took plasma samples from their 1,042 melanoma patients
who were then prospectively observed for a median follow-up of 7.1 years. They found
that lower vitamin D levels in patients with melanoma were associated with increased
tumor thickness ( p < 0.001), ulcerated tumors (p = 0.0105), increased CRP (p < 0.001),
later stage of melanoma ( p = 0.0024) and poorer overall melanoma-specific survival (p =
0.0025) as well as disease free survival ( p = 0.0466). One limitation of this study is that
the population was drawn from one large cancer facility and it may not be representative
of the overall population. There was also no measure of vitamin D supplementation or
intake of the participants, which may have played a role on the serum vitamin D levels
observed.8
Vinceti et al. examined the relationship between dietary vitamin D intake and
melanoma risk in a northern region of Italy known to have a lower vitamin D intake than
many western societies. They used a population-based case-control study to examine
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their 380 cases and 719 controls. Using an in-depth food frequency questionnaire this
study found an inverse relationship between dietary vitamin D intake and melanoma risk.
They found this effect to be especially strong in men with phototype IV skin. Some
limitations of this study are that they did not include amounts of sun exposure or any
information about supplements that may have included vitamin D in their study. They
also noted low control group participation which may have skewed the results making the
relationship appear stronger than it was. Lastly, the location of the study has a
homogenous population which may not apply to a broader population.9
Nurnberg et al. compared serum 25-hydroxyvitamin D levels in melanoma
patients at different stages and control patients without melanoma in Germany. They
found a significantly reduced serum vitamin D level in patients with stage IV melanoma
versus those with stage Ia/Ib melanoma (p = 0.006). Their results also showed trends of
greater tumor thickness (p = 0.078) and earlier distant metastasis (p = 0.641) in patients
with low serum vitamin D levels (less than 10 ng/ml.) Limitations of this study include a
smaller sample size of 205 patients with malignant melanoma and no use of any
demographic information to show if the patients were ethnically diverse or representative
of the general population.10
In line with these findings, a UK based 2009 case control comparison and metaanalysis of VDR data found that vitamin D3 level at recruitment was inversely
proportional to Breslow thickness (p = 0.03).11 Another study with similar findings was a
pilot study conducted by Lim et al. in Australia. They retrospectively looked at 109
primary melanoma cases between 2001 and 2013 and their corresponding vitamin D
levels within 6 months of diagnosis. They looked at a number of variables of the
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melanoma cases and found that high serum vitamin D levels were associated with low
Breslow thickness (p = 0.026). They also found that higher levels of vitamin D were
significantly associated with two other positive melanoma prognostic factors including
non-ulcerated tumors (p = 0.0006) and tumors with lower mitotic rates of 1/mm2 (p =
0.036). It is important to note that a single point vitamin D3 value was used for this study
which could lead to a number of confounding effects on the results. A limitation of this
study is they did not factor in data such as sun exposure history, use of supplements, or
skin phototype. 12 All of these studies found consistent results showing that higher
vitamin D levels are likely associated with better melanoma prognostic factors.
To explain some of the findings from different trials in regard to the mechanism
of vitamin D’s effect on melanoma, Spath et al. investigated the biological effects of 1
alpha hydroxycholecalciferol on experimental melanoma models derived from human
melanoma cell lines and in-vivo xenografts. They hoped to establish an explanation of the
biology behind how vitamin D effects melanoma cells. They found that treating these
cells with the 1alpha hydroxycholecalciferol had antiproliferative effects on the
melanoma cells both in-vitro and in-vivo (p < 0.001). Additionally, they saw that the cell
cycle arrested in the treated cells. After providing daily 1alpha hydroxycholecalciferol for
42 days the biological effects of treatment became statistically significant. In addition to
examining cell lines they also tested the serum 25-hydroxycholecalciferol levels in 105
melanoma patients and found that 94% had insufficient vitamin D levels and the 6% of
the melanoma patients with normal levels all had either in-situ or microinvasive cases of
melanoma. Patients were considered vitamin D deficient if they had a serum level of less
than 10 ng/mL. A limitation of this study was the small sample size of patients tested for
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vitamin D levels. This study may help explain the biology behind why vitamin D
supplementation may be beneficial as an adjuvant treatment for melanoma. 13
Cattaruzza et al. conducted a case-control study in Italy with findings congruent
with the high frequency of vitamin D insufficiency in melanoma patients seen in Spath et
al. This study compared the serum vitamin D levels in 137 melanoma patients to 99
healthy controls. They found a statistically significant difference between the serum
vitamin D levels of those with melanoma compared to those without it. 66.2% of their
participants with melanoma were vitamin D deficient (serum vitamin D of ≤ 20 ng/ml)
compared to only 15.2% of healthy controls (p < 0.001). After controlling for a number
of confounders, their results still showed a significant inverse association between
melanoma and vitamin D sufficiency versus insufficiency with a p-value of < 0.001. A
limitation of this study was that they did not correct for sun exposure when adjusting for
confounders. These results suggest that having sufficient levels of vitamin D may be
protective in terms of melanoma risk, although causation cannot be concluded from these
results due to the design of the study.14
Saw et al. is conducting a placebo controlled randomized phase II trial assessing
adjuvant therapy with high dose vitamin D following primary treatment of melanoma in
Australia and New Zealand. They randomized 75 patients with surgically resected stage
IIb, IIc, IIIa and IIIb melanoma. Their primary goal is to assess the safety and feasibility
of using a vitamin D 500,000 IU loading dose followed by an oral dose of 50,000 IU
monthly for two years compared to placebo following excision of melanoma in adult
patients. Results of this study are still pending.15 This study will help further our current
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understanding of what a safe high dose of vitamin D could be in clinical practice moving
forward. Most other studies use a significantly lower dose than this dosing.
In an ongoing randomized double-blind controlled phase III trial conducted by De
Smedt et al., the group is investigating the protective effect of vitamin D throughout and
after participants’ melanoma diagnoses. In this study 500 adult candidates who met the
criteria would be given either a monthly dose of 100,000 IU cholecalciferol or placebo
with the primary end point being relapse free survival. The subjects would be followed
every 3 months for a maximum of 3.5 years. Results have yet to be published for this
study but will be stratified based on the amount of time since diagnosis. One limitation of
this study is that it does not include any information on participants’ skin phototypes
which may play an important factor in vitamin D production and levels at diagnosis.
Additionally, the study is being conducted at a total of four hospitals in Europe which
may not be representative of a diverse patient population.16
A systematic review published in 2020 examined the association between serum
vitamin D levels and risk and/or prognosis of melanoma. They included 25 studies with a
total of 11,166 melanoma cases in their analysis. Using nine studies with very
heterogenous results they found no significant difference in serum vitamin D levels
between the cases and controls. Despite these results, using results from five studies they
did find that there was a significantly higher prevalence of vitamin D deficiency in the
melanoma patients than in the controls. Additionally, using data from 8 studies they
found that serum vitamin D levels were significantly higher in patients with low Breslow
thickness (less than 1 mm) with a p-value of 0.09. Using five studies they also found that
low serum vitamin D levels were associated with significantly higher mortality with a p-
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value of < 0.001. As previously mentioned, one of the major limitations of this metaanalysis is the limited number of studies and very heterogenous results of the studies used
to investigate the association between serum vitamin D status and risk of developing
melanoma. Furthermore, all of the findings in this study were only associations and show
no causality making it important to interpret the results with some caution.17

2.3 Review of Studies Analyzing Possible Confounders
When using vitamin D as an intervention there are many factors including timing
of the blood draw, sun exposure level, use of sunscreen, gender, age, ethnicity, diet,
treatment and comorbid conditions such as cancer and autoimmune diseases that can play
a role in the serum levels obtained.17 Sun exposure has a clear and known effect on
vitamin D levels and in previous studies can have confounding effects on results if
participants are not matched based on sun behavior. Some trials implement self-report
questionnaires about sun exposure to help control for it in their analysis, but these reports
may not reflect the participants sun exposure acurately.6,10,18 BMI could also play a small
role in results due to the volumetric dilution which could affect the amount of vitamin D
necessary to achieve the same serum levels and has been found to be associated with
melanoma in the past.3,12,14 Time of blood draw based on season can also cause variation
and it has been found previously that vitamin D levels are higher in blood draws
conducted in the spring or summer compared to those from the fall or winter.8 Another
factor which could play a role in vitamin D serum levels is the amount of vitamin D
binding protein participants have circulating in their blood.19

21

2.4 Review of Relevant Methodology
2.4.1 Study Design
This study will be a multi-center, randomized controlled trial which is a study
design that has been used by several previous trials looking at vitamin D levels in regard
to melanoma and other cancers. With the use of placebo medication both patients and
researchers will be blinded in the study.2,3,15,16 Block randomization will be used to help
eliminate differences between the groups due the use of multiple sites in this study and to
allow for rolling enrollment.1 All patients will be consented in accordance with the
institutional ethics guidelines and all patient information will be maintained strictly in
accordance with Health Insurance Portability and Accountability Act (HIPAA).

2.4.2 Study Population and Selection Criteria
Inclusion criteria requires all participants to be adult individuals with surgically
treated malignant melanoma between stages IB-III. Participants will be eligible for
inclusion if they are less than one year from diagnosis and can only be included postsurgical excision.15,16 Patients must be willing and able to attend all follow-up visits for
the duration of the study and provide informed consent.15 Unlike previous studies, this
study will only include patients with Fitzpatrick skin types IV, V, or VI which are often
underrepresented groups in previous studies. Patients who are pregnant, have abnormal
serum phosphate or calcium, impaired renal function, known vitamin D sensitivity or
malabsorption will not be included in the study for safety reasons.16 Patients who exhibit
regular sun exposure behavior or use indoor tanning will also be excluded due to their
high levels of endogenous vitamin D.
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2.4.3 Intervention and Method of Administration
The safety of oral vitamin D has been studied and it appears that vitamin D
toxicity would require a minimum of 10,000 IU/day and most likely would not occur at
less than 40,000 IU/day, making the dose used in this study safe to use over an extended
period of time.20 De Smedt et al. used a monthly oral syringe dose of 100,000 IU, had
patients take all doses after the initial dose at home, and self-record taking their
medication adherence in a diary.16 Scragg et al. used a similar intervention but used
monthly 100,000 IU oral capsules that were mailed to the participants’ homes and
similarly had them self-record their adherence.2 Saw et al. used a slightly different
method of beginning with a 500,000 IU oral loading dose followed by self-administered
and recorded 50,000 IU monthly doses for 23 months.15 Unlike the previous trials
Manson et al. used daily vitamin D dosing of 2,000 IU.3 Similar to that trial, Lappe et al.
used daily 2,000 IU vitamin D but with the addition of 1,500 mg/d of calcium as their
intervention over a four year trial.1 In hopes to improve adherence by making medication
once weekly and increase frequency of dosing we propose using a once weekly oral
vitamin D dose of 25,000 IU which would be the equivalent monthly dose of 100,000 IU
used by previous studies.2,5,16

2.4.4 Outcome Measures
The primary outcome measure of this study will be relapse free survival over the
duration of the trial. Other variables will include stage, location of melanoma, and result
based on Fitzpatrick skin type. To most effectively analyze the results we will be using a
Kaplan-Meier survival curve.15 Data will be collected at every three month follow-up
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visit with the patient’s primary dermatologist including a full-body skin check assessing
for melanoma recurrence or relapse.16 Participants will continue their supplementation
and be followed for 18 months after enrollment into the study.

2.4.5 Safety Concerns
Baseline laboratory tests will be taken at the beginning of the study and
subsequent lab tests for safety and monitoring will be taken at every three month follow
up visit.16 Other studies have similarly checked different patient health information such
as serum corrected calcium, phosphate, eGFR, liver function tests, calcium/creatinine
ratios, tumor status and adherence to dosing regimens during follow-up visits to assess
for safety concerns. For safety reasons participants will cease treatment if any of these
previous lab findings are > 20% above normal range, if the participant becomes pregnant,
has disease progression or develops a renal calculus.15

2.4.6 Sample Size Calculation
The proposed study will examine the efficacy of vitamin D3 as an adjuvant
treatment for surgically resected malignant melanoma in stages IB through III. There are
no prior completed clinical trials, and accordingly this sample size calculation was
performed using data from previous research. A 2019 retrospective cohort study
examining 1931 cases of invasive melanoma found a recurrence rate of 8.8% in stages IIII.21 This expected percent recurrence was used for the sample size calculation as it
covers stages I-III and is on the low side of reported relapse rates in the studies analyzed
which makes it more realistic in the proposed timeframe of this study. A hazard ratio of
0.40 was used for the treatment group and is consistent with the intermediate effect size
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of vitamin D supplementation seen in the Newton-Bishop et al. study.16,22 Drop-out and
non-adherence will also be accounted for at a higher rate than most similar studies as our
study design limits the amount of UV exposure participants can get and requires followup every three months for 18 months. Accordingly, the sample size of this proposed study
will account for a 25% drop out rate.

2.5 Conclusion
In conclusion, there are a number of studies whose results demonstrate an inverse
relationship between serum vitamin D levels and poor melanoma prognostic factors
including increased Breslow thickness, ulceration, and later stage of melanoma.7,8,10,12,17
Studies have also shown a decline in some cancers and more specifically melanoma
mortality with higher vitamin D levels.4,5,17 These effects are likely due to the
antiproliferative effects of vitamin D that have been seen both in-vitro and in-vivo.13
There is also evidence of an inverse relationship between dietary vitamin D and
melanoma risk which was found to be most significant in participants with skin
phototype IV.9 Some studies have also shown there to be a significantly higher
prevalence of vitamin D insufficiency/deficiency in melanoma patients compared to the
general population. 13,14,17 These findings combined would suggest that supplementing
vitamin D in populations where levels are known to be low could provide the patients
with better chances of survival and may decrease rates of relapse.
This study will be the first study to assess whether supplementation with high
dose vitamin D in melanoma patients with Fitzpatrick skin types IV, V, VI would be a
beneficial adjuvant treatment to decrease relapse. By conducting this study, we will gain
insight on whether vitamin D supplementation may be beneficial in populations that are
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known to have lower vitamin D levels at baseline and could provide a relatively safe
adjuvant option in these populations.
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Chapter III: Methods
3.1 Study Design
This study is a multi-centered, double-blind, randomized controlled trial to evaluate the
efficacy of supplemental vitamin D3 for the reduction of recurrent melanoma after wide
local surgical excision in Fitzpatrick skin type IV, V and VI melanoma patients.

3.2 Study Population and Sampling
The study population will be patients from nine cancer centers across the USA who meet the
inclusion and exclusion criteria. Blocked randomization stratified by site will be used to
form the study populations.

3.2.1 Inclusion Criteria
Adults between the age of 18-80 diagnosed and surgically treated for cutaneous
malignant melanoma will be enrolled. The participants must have histologically proven
malignant melanoma with a high risk of recurrence (stages IB-III.) Patients with a
diagnosis within the past year are eligible for enrollment and will only be included after a
complete surgical resection of the melanoma has been performed. Additionally,
participants will be required to have Fitzpatrick skin types IV, V or VI. Participants must
be willing and able to come into the clinic for follow-up every three months for the
duration of the study.
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3.2.2 Exclusion Criteria
Pregnant patients and those who have abnormal entry serum phosphate or
calcium, impaired renal function, known hyperparathyroidism, known vitamin D
sensitivity, history of malabsorption, or chronic alcohol use will be excluded from the
study. Patients participating in any other trials or taking any drugs known to interact with
vitamin D will also be excluded. Patients exhibiting regular sun exposure behavior or
indoor tanning behavior will be excluded.

3.3 Recruitment
Recruitment will take place at numerous centers across the United States including:
Yale New Haven Smilow Cancer Center (New Haven, CT), UCSF Health (San Francisco,
CA), Sloan Kettering Cancer Center (New York, NY), Dana Farber Cancer Center (Boston,
MA), MD Anderson Center (Houston, TX), Mayo Clinic (Jacksonville, FL), Mayo Clinic
(Scottsdale, AZ), USC/Norris Comprehensive Cancer Center (Los Angeles, CA) and the
Harold C. Simmons Comprehensive Cancer Center (Dallas, TX). Due to the use of multiple
sites, block randomization will be performed at each individual site. The dermatology clinics
in these sites will be asked to participate in this study and for help recruiting eligible
patients. Patients who meet the inclusion criteria who express interest in participating will
be enrolled in the study if they have undergone surgical excision for stage IB-III melanoma.
They will then sign informed consent forms (Appendix A) and be assessed against the
exclusion criteria prior to randomization.
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3.4 Subject Protection and Confidentiality
We will obtain approval by Yale’s oncology-focused Institutional Review Board (IRB) and
Human Investigation Committee (HIC).

Submitting an application to the HIC IRB committee involves a four-step process:
1. All personnel interacting with patients or data must undergo Human Subjects
Protection Training.
2. All personnel interacting with patients or data must complete HIPAA training.
3. The principal investigator and co-investigators must file a financial disclosure
form with the Yale Conflict of Interest office.
4. Once all the prior steps have been met, the investigators may submit an application
to the HIC IRB committee through the IRES IRB system. The application will be
submitted to: https://your.yale.edu/research-support/human-research/yale-irbsyale-university-institutional-review-boards/ires-irb

Throughout the study, confidentiality of participants will be strictly maintained in
accordance with HIPAA. To ensure confidentiality, each participant will be assigned a
randomly generated identification number which will be used throughout the duration of the
study. All electronic records will be kept in encrypted databases on password protected
computers, and access to the patient records will only be available to the dermatology teams
performing direct patient care. Other study personnel such as research assistants will only
have access to de-identified data.
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3.5 Study Variables and Measures
Participants who have met the inclusion criteria will be randomized to two groups:
either the control group, which will receive the standard of care and placebo, or the
intervention group, which will receive the oral vitamin D3 supplement. At enrollment of
each subject, a baseline serum 25(OH)D level and a complete metabolic panel (CMP) of all
participants will be obtained and patient information will be reviewed to ensure that they
meet the inclusion/exclusion criteria. These same tests will be obtained at every three month
follow-up visit to monitor patient adherence and possible side effects.
The intervention group will receive oral vitamin D3 (cholecalciferol) 25,000 IU once
weekly for the duration of the study. The control group will receive a capsule identical in
appearance to the intervention group. Both groups will be instructed to take the capsule
with the same frequency and return for the same regularity of monitoring including blood
tests and total body skin checks to evaluate for melanoma recurrence.
All subjects will use a wireless, battery-free miniature ultraviolet light dosimeter
to monitor their ultraviolet light exposure. Since sun exposure of the skin is the most
efficient method to obtain vitamin D, it will be important to monitor endogenous
production to control for these effects.1
The primary outcome of the study will be the efficacy of the treatment measured by
the difference in relapse-free survival in the intervention vs. placebo group. Other
variables will include stage, location of melanoma, and Fitzpatrick skin type.
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3.6 Assignment of Intervention and Blinding
At each of the study locations rolling recruitment and block randomization will be
used. Participants will be allocated to the control vs. intervention group in a 1 to 1 fashion
with a block size of two. Recruitment will end once a sample of 70 total participants is met.
After randomization, the participants will be assigned their randomly generated unique
identification number to de-identify their personal information. Patients and study personnel
will all be blinded to the patient’s study treatment allocation and vitamin D levels by use of
the unique identification numbers.

3.7 Data Collection
Clinicians at each site will identify eligible patients, and those who show interest
will sign informed consent forms. Patients will undergo a full body skin examination and
will have a complete metabolic panel and serum 23 hydroxyvitamin D (23 OHD) level
checked for baseline levels on the day of enrollment. Participants that meet the inclusion and
exclusion criteria will be randomized and assigned to a treatment group. They will then be
asked to return within the next week to meet with a research assistant, obtain their first
three-month supply of either the placebo or vitamin D3 and to complete a demographic
survey. Patients will receive explicit instructions on dosage, frequency, and adherence to the
medication required to remain in the study. At every three month follow up, data will then
be collected by the patient’s dermatologist via full body skin check and CMP, and the
patients will receive a new three-month supply of the medication. Side effects and Vitamin
D3 concentrations will be monitored throughout the duration of the study.
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3.8 Adherence
Adherence will be monitored through weekly patient logs. They will be offered either
paper or electronic log options. The patient will be given a sheet of paper with their pill
bottle that has all the weeks listed and a space for a check mark if they have taken their dose
for the week. The patient will be asked to bring these logs to each visit. Electronic logs can
be completed via phone applications (such as Medisafe, Carezone, Pill Logger, Medica etc.)
and can be shared with their providers. To improve adherence, we will also ask all the
patients to set a weekly recurring reminder for the day of the week they choose to take
their medication.

3.9 Monitoring of adverse events and safety
At the beginning of the study baseline laboratory tests will be checked.
Subsequent lab tests for safety and monitoring will be checked at every three month
follow up visit.2 Different patient health information measures such as serum corrected
calcium, phosphate, eGFR, liver function tests, calcium/creatinine ratios, and tumor
status during follow-up visits to assess for safety concerns will be checked. For safety
reasons, participants will cease treatment if any of these previous lab findings are > 20%
above normal range, or if the participant becomes pregnant.3

3.10 Sample Size Calculation
Using the Power and Precision 4 software, a sample size of 56 participants using a
two-tailed test and alpha of 0.05 was determined. This sample size will allow 80% power to
detect whether vitamin D supplementation increased relapse free survival with an accrual
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period of 6 months. The sample size calculation was based on two previous studies
discussed in Chapter II. Adjusting for a 25% dropout/non-adherence rate, the recruitment
goal will be 70 participants to be randomized and enrolled into the study. The participants
will be randomized in a 1:1 fashion, with a total of 35 participants in each group. The
sample size calculation is included in Appendix B.

3.11 Analysis
The primary analysis will be an intent-to-treat analysis of all randomized patients.
Analysis will evaluate relapse free survival with a Kaplan Meier time-to event survival
curve. Results will be considered to be statistically significant if they have a p-value of
less than 0.05. a per protocol analysis will be performed in anticipation of a high noncompliance/dropout rate and an intention-to-treat analysis will likely skew the results
towards the null. Demographic data including age, sex, ethnicity, race, stage of
melanoma and location will be collected for all patients to compare the treatment and
control groups. The categorical variables such as sex, stage of melanoma, and race will
be compared using a chi-square test. Age will be compared using an independent sample
t-test.

3.12 Timeline and Resources
The total duration of this study including recruitment, randomization and data
collection will be two years. Rolling recruitment and enrollment will begin January 2021
and will continue for six months to allow for follow-up and data collection. All of the sites
chosen for this study are high volume cancer and melanoma facilities, and accordingly, there
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should not be any difficulty obtaining the 70 participants needed for this study. All study
subjects will have to meet with a research assistant in the first week of enrollment to receive
their medication and trial instructions. Follow up visits will be conducted by their clinical
dermatologist every three months for routine melanoma follow-up and data collection. Data
collection will end at the beginning of January 2023.
The study will be headquartered in New Haven, CT. Dr. Suguru Imaeda and Shikha
Goyal PA-SII will be the primary investigators for this project. Each site will have its own
research assistant who will be responsible for identifying and confirming participants who
meet the inclusion and exclusion criteria, obtaining informed written consent, and discussing
data collection with the dermatologist treating the enrolled patients. They will also be
responsible for meeting with the participants following enrollment into the study to provide
them with instructions on adherence and follow-up. The patient’s dermatologist will be
provided with the patient’s medication including either the three-month supply of weekly
25,000 IU vitamin D3 pills or the matching placebo to be given at each follow-up
appointment.
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Chapter IV: Conclusion
4.1 Advantages and Disadvantages
There are a number of strengths to this proposed study. It will be the first clinical
trial investigating the use of high dose vitamin D therapy as an adjuvant treatment in
patients with Fitzpatrick skin types IV-VI. There are currently a couple of ongoing
studies looking at vitamin D use in other populations. However, none of these studies
incorporate the differences in Fitzpatrick skin type and the according difference in
vitamin D endogenous synthesis.1,2 Although sun exposure is a known confounder of
vitamin D levels, previous studies in this field rarely accounted for sun exposure in a
systematic manner. Most previous studies have not been randomized controlled trials and
accordingly have only been able to establish association and not causation.3-6
The use of this study design and double blinding will also decrease selection bias
that could influence the results. Block randomization and stratification by site should
ensure that the populations are similar, reduce selection bias, and minimize the effects of
other confounders. The sufficient sample size of this trial ensures that the study is
powered to show causation and also allows the study to withstand participant dropout that
would occur in a study of this length. The use of multiple sites will allow us to meet our
target study population size within the recruitment period and will also ensure that the
results are generalizable to the larger community of individuals with Fitzpatrick skin
types IV-VI. Melanoma patients often follow up with their dermatologist every three
months. Using these visits with the participant’s primary dermatologist for data collection
increases the feasibility, decreases the cost, and should promote adherence.

38

Despite the many advantages of this design, there are some disadvantages. A
limitation of this study is the shorter duration of follow-up compared to similar studies.
However, since over half of relapses occur within two years of excision of the primary
melanoma this study will add important information on whether vitamin D3 is an
effective adjuvant treatment in this population. A longer duration would allow for more
data collection and a more complete ability to assess differences between relapse in the
treatment and placebo groups. Another disadvantage of the study is that the use of many
clinical sites could lead to some differences in how the study is conducted between sites.
These differences will be minimized by providing standard instructions to all sites,
providers, and research assistants. There is also not an established ideal dose for highdose adjuvant vitamin D therapy. Accordingly, this study is using overall dosing in line
with other previous studies, but breaking up the dosing to weekly due to evidence that
higher frequency of dosing may be more beneficial.2,7,8 By limiting the study to those
with Fitzpatrick skin types IV-VI it is also important to note that these results would not
be generalizable to those with fairer complexions.

4.2 Clinical and/or Public Health Significance
Melanoma continues to be the deadliest form of skin cancer, and even after
surgical removal it is known to have high rates of relapse and recurrence.1 Despite this,
there is still a lack of safe and effective adjuvant options for melanoma patients.9 Vitamin
D is known to have anticarcinogenic and antimelanoma effects which have been seen invivo and in-vitro.10-12 People of color with Fitzpatrick skin types IV-VI have often been
underrepresented in study populations examining skin cancer where differences in
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pigmentation may play an important role. Due to differences in synthesis, it is more
difficult for those with more epidermal melanin to produce endogenous vitamin D from
sunlight, leading to the higher rates of vitamin D deficiency seen in darker skinned
individuals.13-15 These differences may make the role of vitamin D supplementation
especially useful in populations with Fitzpatrick skin types IV-VI. It has also been found
that, despite lower incidence of melanoma in non-white populations, when melanoma is
found in this population, it is often detected at more advanced stages, with thicker
lesions, increased rate of metastasis and poorer outcomes.16
This study will provide some of the strongest evidence to date to guide whether
vitamin D supplementation could act as a useful adjuvant treatment in patients with
Fitzpatrick skin types IV, V and VI. If successful it could provide a new clinically
supported, low toxicity, adjuvant treatment option. This study has the unique advantage
of accurately measuring and accounting for UV sun exposure, a known confounder of
vitamin D levels that has rarely been controlled for in previous related studies. This study
will additionally help establish if this dosing of vitamin D is clinically useful and safe.
The results of the proposed study would be a logical addition to the existing body of
literature, clarifying vitamin D’s utility as an adjuvant treatment in surgically resected
melanoma cases in a population with an increased risk of vitamin D deficiency.
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Appendices
Appendix A. Sample HIC Consent Form

CONSENT FOR PARTICIPATION IN A RESEARCH
PROJECT
YALE UNIVERSITY SCHOOL OF MEDICINE

Study Title: Vitamin D Supplementation In Fitzpatrick Skin Types IV-VI As An
Adjuvant Treatment For Malignant Melanoma
Principal Investigator: Suguru Imaeda, MD
Funding Source:
Invitation to Participate and Description of Project
We are inviting you to participate in a research study designed to look at
whether supplementation with vitamin D reduces risk of melanoma recurrence in
adults with Fitzpatrick skin types IV-VI who have been diagnosed and treated for
cutaneous melanoma. You have been asked to participate because you are an adult
between the age of 18-80 that has had a surgically treated malignant melanoma
between stages IB-III, are less than one year from diagnosis and have had the tumor
surgically excised. Approximately 70 persons will participate in the study.
In order to decide whether you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This consent
form gives you detailed information about the research study, which a member of the
research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits and possible alternative treatments. Once you understand the study,
you will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
If you agree to participating in this study, you will be randomly assigned to (a) the
control group, which will receive the standard of care and placebo OR (b) the intervention
group, which will receive the oral vitamin D3 supplement. The study has a total duration
of 18 months.
If you are pregnant or may become pregnant, if you have abnormal entry serum
phosphate or calcium, impaired renal function, known hyperparathyroidism, known
vitamin D sensitivity, history of malabsorption, or chronic alcohol use, you cannot
participate in this study. If you are participating in any other trials or taking any drugs
known to interact with vitamin D you will also be excluded. If you have regular sun
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exposure behavior or indoor tan you will be excluded.
If you agree to be enrolled in this study, a baseline serum 25(OH)D level and a
complete metabolic panel (CMP) will be taken and your information reviewed to
ensure that you meet the inclusion/exclusion criteria. These same tests will be
performed at every three-month follow-up visit to monitor your adherence and possible
side effects.
The intervention group will receive an oral vitamin D3 25,000 IU once weekly for the
duration of the study. The control group will receive a capsule identical in appearance
to the intervention group. Both groups will be instructed to take the capsule with the
same frequency and return for the same regularity of monitoring including blood tests
and total body skin checks to evaluate for melanoma recurrence.
You will also be given a wireless, battery-free miniature ultraviolet light dosimeter to
monitor your ultraviolet light exposure.
A description of this study is available on http://www.ClinicalTrials.gov, as required
by U.S. Law. This website will not include information that can identify you. The
purpose of this database is to allow everyone to see information on what studies are
being done, and what studies have been done. At most, the Web site will include a
summary of the results. You can search this website at any time.
You will be told of any significant new findings that are developed during the course of
your participation in this study that may affect your willingness to continue to
participate. Research results will not be returned to your doctor. If research results are
published, your name and other personal information will not be given.
Risks and Inconveniences
Vitamin D Supplementation has been studied in several clinical trials for many
conditions. The safety of oral vitamin D has been studied and it appears that vitamin D
toxicity would require a minimum of 10,000 IU/day and most likely would not occur
at less than 40,000 IU/day, making the dose used in this study safe to use over an
extended period of time.
If you are pregnant or may become pregnant, if you have abnormal entry serum
phosphate or calcium, impaired renal function, known hyperparathyroidism, known
vitamin D sensitivity, history of malabsorption, or chronic alcohol use, you cannot
participate in this study. If you are participating in any other trials or taking any drugs
known to interact with vitamin D you will also be excluded. If you have regular sun
exposure behavior or indoor tan you will be excluded.
Other risks from participating in the study include the breach of confidentiality about
your health status and participation in the study. This is very unlikely to occur, as all
study investigators are trained and certified in research privacy and this is a double
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blinded study.
We will also ask you to have your baseline serum 25(OH)D level and a complete
metabolic panel (CMP) done at every three-month follow-up visit to monitor your
adherence and possible side effects. The risks involved in drawing blood from a vein
may include, but are not limited to, momentary discomfort at the site of the blood
draw, possible bruising, redness, and swelling around the site bleeding at the site,
feeling of lightheadedness when the blood is drawn, and rarely, an infection at the site
of the blood draw. There are no major risks associated with these procedures.

44

Benefits
There are potential benefits resulting from the study including a lower rate of relapse of
melanoma compared to those not receiving vitamin D supplementation, and that this
research may lead to new treatments in the future.
Economic Considerations
The vitamin D or placebo will be provided free of charge. There are no other costs
associated with your participation in the study. Parking will be provided free of charge.
Treatment Alternatives/Alternatives
If you choose not to participate in this study, there are no alternative treatments
available, except those that are already being administered by your physician including
pharmacotherapy (medications/drugs), surgery, and lifestyle changes. You may choose
not to participate.
Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include
abuse of a child or elderly person, or certain reportable diseases. Information will be
kept confidential by using only identification numbers on study forms, storing signed
forms in locked cabinets, and password protecting data stored on a computer. When
the results of the research are published or discussed in conferences, no information
will be included that would reveal your identity unless your specific permission for
this activity is obtained.
We understand that information about your health is personal, and we are committed
to protecting the privacy of that information. If you decide to be in this study, the
researcher will get information that identifies your personal health information. This
may include information that might directly identify you, such as his or her name and
address, telephone number, and email address, or mobile phone number. This
information will be de-identified at the earliest reasonable time after we receive it,
meaning we will replace your identifying information with a code that does not
directly identify you. The principal investigator will keep a link that identifies you and
your coded information, and this link will be kept secure and available only to the
principal investigator or selected members of the research team. Any information that
can identify you will remain confidential. Information will be kept confidential by
using only identification numbers on study forms, storing signed forms in locked
cabinets, and password
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protecting data stored on a computer. The research team will only give this coded
information to others to carry out this research study. The link to your personal
information will be kept for 5 years, after which time the link will be destroyed and the
data will become anonymous. The data will be kept in this anonymous form
indefinitely.
The information about your health that will be collected in this study includes:
• Research study records
• Records about phone calls made as part of this research
• Records about your study visits
Information about your health which might identify your child may be used by or given
to:
• The U.S. Department of Health and Human Services (DHHS) agencies
• Representatives from Yale University, the Yale Human Research
Protection Program and the Yale Human Investigation Committee (the
committee that reviews, approves, and monitors research on human
subjects), who are responsible for ensuring research compliance. These
individuals are required to keep all information confidential.
• Those individuals at Yale who are responsible for the financial oversight
of research including billings and payments
• The Principal Investigator (Dr. Suguru Imaeda)
• Co-Investigators and other investigators
• Study Coordinator and Members of the Research Team
By signing this form, you authorize the use and/or disclosure of the information
described above for this research study. The purpose for the uses and disclosures
you are authorizing is to ensure that the information relating to this research is
available to all parties who may need it for research purposes.
All health care providers subject to HIPAA (Health Insurance Portability and
Accountability Act) are required to protect the privacy of your information. The
research staff at the Yale School of Medicine are required to comply with HIPAA
and to ensure the confidentiality of your information.
If you choose to participate in this study, the research assistants will check your
electronic medical record at Yale (EPIC) to make sure you qualify. Any access to
your electronic medical record will be done consistent with HIPAA regulations.
Some of the individuals or agencies listed above may not be subject to HIPAA and
therefore may not be required to provide the same type of confidentiality protection.
They could use or disclose your information in ways not mentioned in this form.
However, to better protect your health information, agreements are in place with
these individuals and/or companies that require that they keep your information
confidential.
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You have the right to review and copy your health information in your medical record
in accordance with institutional medical records policies. This authorization to use
and disclose your health information collected during your participation in this study
will never expire.

Voluntary Participation and Withdrawal
You are free to choose not to participate in this study. Your health care outside the
study, the payment for your health care, and your health care benefits will not be
affected if you do not agree to participate. However, you will not be able to enroll in
this research study and will not receive study procedures as a study participant if you
do not allow use of your information as part of this study. You do not give up any of
your legal rights by signing this form.
Withdrawing From the Study
If you do not become a subject, you are free to stop and withdraw from this study at any
time during its course.
To withdraw from the study, you can call a member of the research team at any time
and tell them that you no longer want to take part. This will cancel any future
appointments.
The researchers may withdraw you from participating in the research if necessary. This
will only occur if you do not attend the assigned weekly sessions.
If you choose not to participate or if you withdraw it will not harm your relationship
with your own doctors or with the Yale School of Medicine and Yale New-Haven
Hospital.
Withdrawing Your Authorization to Use and Disclose Your Health Information
You may withdraw or take away permission to use and disclose your health
information at any time. You do this by calling or sending written notice to the
Principal Investigator, Dr. Suguru Imaeda Department of Dermatology, Yale School of
Medicine.
When you withdraw your permission, no new health information identifying you will
be gathered after that date. Information that has already been gathered may still be
used and given to others until the end of the research study, as necessary to ensure the
integrity of the study and/or study oversight.
You do not give up any of your legal rights by signing this form.
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Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and to consider this research and the permission form carefully –
as long as you feel is necessary – before you make a decision.

Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My
signature also indicates that I have received a copy of this consent form.

Name of Subject:
Signature:
Relationship:
Date:

Signature of Principal Investigator

Date

or

Signature of Person Obtaining Consent

Date

If you have further questions about this project or if you have a research-related
problem, you may contact the Principal Investigator, Dr. Suguru Imaeda at 203415-9221.
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you
may have concerning this research, or to discuss your rights as a research subject, you
may contact the Yale Human Investigation Committee at (203) 785-4688.
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Appendix B: Sample Size Calculation

Alpha (level of significance): 0.05
Power: 80%
2-tailed hypothesis
N = 28 per group
Factoring in an expected 25% dropout rate the sample size is n=35 per group
Calculated using: Power and Precision 4.
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